NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=135481&from=4 CLASS PERIOD: ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Investors who purchased a significant number of shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and there are short and strict deadlines running. Deadline: April 7, 2025. NASDAQ: NMRA investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.On February 06 ...

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/ ...

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=134598&from=4 CLASS PERIOD: ...

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tra ...

RADNOR, Pa., March 6, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the "Offering Documents") issued in connection with Neumora's initial public offering held on or arou ...

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will present at the Leerink Global Healthcare Conference being held in Miami, FL on Tuesday, March 11, 2025 at 10:00 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of the Company’s websi ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tra ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s September 2023 initial public offering (the “IPO”), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If ...

Financial Data and Key Metrics Changes - Total operating expenses for Q4 2024 were $58.8 million, a decrease from $108.7 million in Q4 2023 [32] - Total operating expenses for the full year 2024 were $243.8 million, compared to $235.9 million in 2023, indicating a slight increase [32] - As of December 31, 2024, the company had $307.6 million in cash, cash equivalents, and marketable securities, expected to support operations into mid-2026 [33] Business Line Data and Key Metrics Changes - Navacaprant is in Phase 3 development for MDD, with significant changes made to optimize ongoing studies based on KOASTAL-1 learnings [11][12] - NMRA-511 is being investigated in a Phase 1b study for Alzheimer's disease agitation, targeting a significant unmet need [15][16] - The M4 franchise is expected to progress into the clinic by mid-2025, with confidence in its PAM mechanism [17][28] Market Data and Key Metrics Changes - MDD affects over 280 million people globally, representing a substantial market opportunity for navacaprant [11] - Approximately 70% of the estimated 7 million people with Alzheimer's disease experience agitation, highlighting the need for effective treatments [16] Company Strategy and Development Direction - The company aims to deliver transformative medicines for brain diseases, focusing on novel mechanisms of action and best-in-class pharmacology [7][10] - A strong financial position allows the company to advance multiple clinical and preclinical programs [8][33] - The strategy includes rigorous prioritization of resources towards the KOASTAL program and other clinical initiatives [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of navacaprant despite challenges faced in the KOASTAL-1 study, viewing the results as potentially anomalous [12][45] - The company is committed to enhancing patient selection and monitoring in upcoming studies to improve outcomes [39][65] - 2025 is anticipated to be a pivotal year for the company, with ongoing efforts to address unmet needs in brain disease treatments [19] Other Important Information - The company has a pipeline of four preclinical programs targeting various brain disorders, including Alzheimer's agitation and schizophrenia [29] - The management team emphasizes the importance of a strong balance sheet and strategic financing options to support ongoing operations [66][70] Q&A Session Summary Question: Differences between vendors for KOASTAL-1 and SAFER - The company is enhancing medical monitoring to confirm independent diagnoses for MDD, utilizing the SAFER approach for verification [38][39] Question: Enrollment status of KOASTAL-2 and 3 - Enrollment numbers are not disclosed, but studies are expected to resume for another 12 to 15 months, with changes aimed at improving outcomes [51][52] Question: Placebo response in KOASTAL-1 - An outsized placebo response was noted, particularly in males, and site experience was identified as a key factor influencing performance [46][65] Question: Cash runway and financing strategies - The company maintains a strong financial position with cash runway extending into mid-2026, exploring various funding mechanisms [66][70] Question: Interim analysis for KOASTAL studies - No interim analysis is planned for KOASTAL-2 and 3 due to the short duration of the studies [87] Question: Update on NMRA-266 clinical hold - The company is working to determine the path forward for NMRA-266 while progressing follow-on compounds in the M4 franchise [92]